The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man
| Status: | Recruiting |
|---|---|
| Conditions: | Endocrine |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/21/2016 |
| Start Date: | March 2015 |
| End Date: | March 2016 |
| Contact: | Dariush E;ahi, PhD |
| Email: | dariush.elahi@iconplc.com |
| Phone: | 210-283-4520 |
To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.
The investigators have previously demonstrated that infusion of the pentapeptide during
hyperglycemic clamps in dogs significantly increases the glucose infusion rate necessary to
maintain stable hyperglycemia without any significant differences in insulin or glucagon
secretion. The present study's aim is to examine whether this also occurs in humans. It may
be necessary to examine a dose response curve. Specifically, in twenty healthy volunteers
glucose infusion rate during the peptide infusion will be compared to the glucose infusion
rate during saline administration during a 4 hour hyperglycemic clamp, in a cross over
design(mg/kg/min).
hyperglycemic clamps in dogs significantly increases the glucose infusion rate necessary to
maintain stable hyperglycemia without any significant differences in insulin or glucagon
secretion. The present study's aim is to examine whether this also occurs in humans. It may
be necessary to examine a dose response curve. Specifically, in twenty healthy volunteers
glucose infusion rate during the peptide infusion will be compared to the glucose infusion
rate during saline administration during a 4 hour hyperglycemic clamp, in a cross over
design(mg/kg/min).
Inclusion Criteria:
- BMI 18.5-25;
- 33-38
Exclusion Criteria:
- T2D
- T1D
- Hypoglycemic agents
We found this trial at
1
site
Click here to add this to my saved trials
